Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 1.00 |
| ▸ | MMP9 | P14780 | 16/20 | 1.00 |
| ▸ | MMP8 | P22894 | 14/20 | 1.00 |
| ▸ | MMP1 | P03956 | 7/20 | 1.00 |
| ▸ | MMP3 | P08254 | 3/20 | 1.00 |
| ▸ | MMP14 | P50281 | 2/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 1/20 | 1.00 |
| ▸ | ADAM12 | O43184 | 1/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 1.00 |
| ▸ | MMP7 | P09237 | 1/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 1.00 |
| ▸ | MMP15 | P51511 | 1/20 | 1.00 |
| ▸ | MMP16 | P51512 | 1/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 1/20 | 1.00 |
| ▸ | ADAM9 | Q13443 | 1/20 | 1.00 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 1.00 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 1.00 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilomastat SCHEMBL29412562 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL7870487 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL4394885 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL6691646 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL8190117 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL35303 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ilomastat SCHEMBL13575799 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL8394283 | 0.92 | MMP2 (0.85) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL4845965 | 0.91 | MMP2 (0.84) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL5558468 | 0.90 | MMP2 (0.82) | MMP2MMP9MMP8MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107106453-B | Skin lightening composition comprising niacinamide and ilomastat | 联合利华知识产权控股有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3932402-A1 | ADAM17 INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF COVID-19 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2022-01-05 | — | — | EP | disclosed |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | NYSNOBIO IRELAND DAC (IE) | 2020-03-19 | — | — | US | disclosed |
| CN-107106454-B | Skin lightening compositions comprising 4-hexylresorcinol and ilomastat | 荷兰联合利华有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-10155936-B2 | Parkin ligase activation methods and compositions | An2H Discovery Limited (IE) | 2018-12-18 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| EP-1984500-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007084488-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155936-B2 | Parkin ligase activation methods and compositions | PINK1, XIAP, STUB1 | MMP2 2913/4885MMP9 3315/4885MMP8 1635/4885 |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | MMP2 2913/4885MMP9 3315/4885MMP8 1635/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | MMP2 223/4885MMP9 97/4885MMP8 299/4885 |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | MMP2 2913/4885MMP9 3315/4885MMP8 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.